This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Audouin, J. Articles by Diebold, J. Search for Related Content PubMed PubMed Citation Articles by Audouin, J. Articles by Diebold, J. Social Bookmarking                         What's this?

Myeloid Sarcoma: Clinical and Morphologic Criteria Useful for Diagnosis

Service "Jacques-Delarue" d'Anatomie et de Cytologie Pathologiques, Hôtel Dieu, Paris, France; Service "Jacques-Delarue" d'Anatomie et de Cytologie Pathologiques, Hôtel Dieu, 1 place du Parvis Notre Dame, 75181 Paris, Cedex 04, France

E. Comperat, MD

A. Le Tourneau, MD

S. Camilleri-Broët, MD

C. Adida, MD

T. Molina, MD

J. Diebold, MD

Service "Jacques-Delarue" d'Anatomie et de Cytologie Pathologiques, Hôtel Dieu, Paris, France

Extramedullary accumulation of myeloblasts or immature myeloid cells form tumors called myeloid sarcoma in the WHO classification. Such tumors develop in lymphoid organs, bone (skull, orbit, etc.), skin, soft tissue, various mucosae and organs, and the CNS. They may precede or occur concurrently with acute myeloid leukemia, or reveal blastic transformation of chronic myeloproliferative disorders or myelodysplastic syndromes. They may also reveal relapses in treated patients. They are constituted by a diffuse infiltrate made up of medium-to-large cells. The cells are difficult to identify. Imprints are very useful. Immunohistochemistry can help diagnose and distinguish four variants: granulocytic myeloperoxidase (MPO+, CD 68+ [KP1, PGM1-] lysozyme+, CD 34), monoblastic (MPO-, CD 68+, [KPI+, PGMI+] lysozyme+, CD 34-), myelomonoblastic (MPO-, CD 68+, [KPI+, PGM1+] lysozyme+, CD 34-), or megakaryoblastic (positivity for factor VIII, CD 61, CD 31). Immunohistochemistry sometimes demonstrates expression of CD 43, CD 7, CD 79a, and CD 56 (particularly the monoblastic variant with t[8;2 1]). Recently the demonstration of CD 99 and CD 1 7, which can now be done on paraffin sections, may be useful to identify blasts of granulocytic origin. The diagnosis is missed in about 50% of cases when immunohistochemistry is not used. Patients with myeloid sarcomas should be treated in the same way as patients with acute myeloblastic leukemia. Disease progression and prognosis are similar for the two conditions.

Key Words: myeloid sarcoma • granulocytic sarcoma

International Journal of Surgical Pathology, Vol. 11, No. 4, 271-282 (2003)
DOI: 10.1177/106689690301100404


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?